Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Blepharitis - Drug Profiles
(doxycycline + omega 3 fatty acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-13002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-270 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Tarsus Pharmaceuticals announces positive results of the mars study, a phase 2a study of the efficacy and safety of TP-03 to treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting
Apr 08, 2020: Nicox outlines plans to progress NCX 4251 into phase 2b trial following positive meeting with FDA
Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigatiol New Drug Application for NCX 4251 phase 2 trial in Blepharitis
Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by AxeroVision Inc, H2 2020
Blepharitis - Pipeline by Azura Ophthalmics Ltd, H2 2020
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Hovione FarmaCiencia SA, H2 2020
Blepharitis - Pipeline by Merck & Co Inc, H2 2020
Blepharitis - Pipeline by NicOx SA, H2 2020
Blepharitis - Pipeline by Novaliq GmbH, H2 2020
Blepharitis - Pipeline by Premark Pharma GmbH, H2 2020
Blepharitis - Pipeline by Quorum Innovations LLC, H2 2020
Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, H2 2020
Blepharitis - Dormant Projects, H2 2020